Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical TrialStefano Rusconi, Giulia Marchetti, Luca Butini et al.|PLoS ONE|2013Cited by 42
HIV-1 Residual Viremia and Proviral DNA in Patients with Suppressed Plasma Viral Load ( < 400 HIV-RNA cp/ml) During Different Antiretroviral RegimensEmanuele Nicastri, Massimo Andreoni, Lucia Palmisano et al.|Current HIV Research|2008Cited by 32
Cellular HIV‐1 DNA quantitation in patients during simplification therapy with protease inhibitor‐sparing regimensLoredana Sarmati, Massimo Andreoni, Saverio Giuseppe Parisi et al.|Journal of Medical Virology|2007Cited by 23
High Prevalence of M184 Mutation among Patients with Viroimmunologic Discordant Responses to Highly Active Antiretroviral Therapy and Outcomes after Change of Therapy Guided by Genotypic AnalysisEmanuele Nicastri, Massimo Andreoni, Loredana Sarmati et al.|Journal of Clinical Microbiology|2003Cited by 18
Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral TherapyEmanuele Nicastri, Massimo Andreoni, Loredana Sarmati et al.|AIDS Research and Human Retroviruses|2004Cited by 13